Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
IDS
cytoreductive surgery
neoadjuvant
ovarian cancer
progression-free survival
time interval
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
28
05
2023
revised:
18
06
2023
accepted:
26
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
There is limited data on the optimal time interval between the last dose of neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC). We retrospectively identified patients with stage IIIC/IV HGSC who received NACT followed by IDS during a 15-year period (January 2003-December 2018) in our Institution. Overall, 115 patients with stage IIIC/IV HGSC were included. The median age of diagnosis was 62.7 years (IQR: 14.0). A total of 76.5% (88/115) of patients were diagnosed with IIIC HGSC and 23.5% (27/115) with IV HGSC. Median PFS was 15.7 months (95% CI: 13.0-18.5), and median OS was 44.7 months (95% CI: 38.8-50.5). Patients were categorized in groups according to the time interval from NACT to IDS: <4 weeks (group A); 4-5 weeks (group B); 5-6 weeks (group C); >6 weeks (group D). Patients with a time interval IDS to NACT ≥4 weeks had significantly shorter PFS ( We have demonstrated that performing IDS within four weeks after NACT may be associated with better survival outcomes. Multidisciplinary coordination among ovarian cancer patients is required to avoid any unnecessary delays.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited data on the optimal time interval between the last dose of neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC).
METHODS
METHODS
We retrospectively identified patients with stage IIIC/IV HGSC who received NACT followed by IDS during a 15-year period (January 2003-December 2018) in our Institution.
RESULTS
RESULTS
Overall, 115 patients with stage IIIC/IV HGSC were included. The median age of diagnosis was 62.7 years (IQR: 14.0). A total of 76.5% (88/115) of patients were diagnosed with IIIC HGSC and 23.5% (27/115) with IV HGSC. Median PFS was 15.7 months (95% CI: 13.0-18.5), and median OS was 44.7 months (95% CI: 38.8-50.5). Patients were categorized in groups according to the time interval from NACT to IDS: <4 weeks (group A); 4-5 weeks (group B); 5-6 weeks (group C); >6 weeks (group D). Patients with a time interval IDS to NACT ≥4 weeks had significantly shorter PFS (
CONCLUSION
CONCLUSIONS
We have demonstrated that performing IDS within four weeks after NACT may be associated with better survival outcomes. Multidisciplinary coordination among ovarian cancer patients is required to avoid any unnecessary delays.
Identifiants
pubmed: 37444629
pii: cancers15133519
doi: 10.3390/cancers15133519
pmc: PMC10340433
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Eur J Cancer. 2016 Sep;64:22-31
pubmed: 27323348
J Thorac Oncol. 2017 Feb;12(2):314-322
pubmed: 27720827
Eur J Surg Oncol. 2017 Apr;43(4):613-618
pubmed: 27793416
Ann Surg Oncol. 2016 May;23(5):1515-21
pubmed: 26678405
Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056
pubmed: 31263024
Gynecol Oncol. 2018 Jan;148(1):62-67
pubmed: 29174056
Eur J Surg Oncol. 2003 Feb;29(1):69-73
pubmed: 12559080
Int J Colorectal Dis. 2022 Apr;37(4):855-868
pubmed: 35279746
Eur J Cancer. 2017 Jan;70:133-142
pubmed: 27914243
J Cancer. 2018 Oct 18;9(21):4087-4091
pubmed: 30410613
Gynecol Oncol. 2018 Sep;150(3):446-450
pubmed: 30001834
J Clin Oncol. 2015 Aug 1;33(22):2457-63
pubmed: 26124480
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Gynecol Oncol. 2020 Jun;157(3):599-605
pubmed: 32173048
Gynecol Oncol. 2008 Sep;110(3):354-9
pubmed: 18572226
Eur J Cancer. 2013 Jan;49(1):142-9
pubmed: 22921185
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Lancet. 2019 Dec 7;394(10214):2084-2095
pubmed: 31791688
J Gynecol Oncol. 2020 Sep;31(5):e86
pubmed: 32808504
J Ovarian Res. 2021 Mar 27;14(1):49
pubmed: 33771198
Ann Surg Oncol. 2006 Aug;13(8):1156-61
pubmed: 16791447
Zhonghua Fu Chan Ke Za Zhi. 2021 Jun 25;56(6):385-392
pubmed: 34154313